MPP recently provided testimony to an FDA panel charged with re-examining dental amalgam. We pointed out that while FDA panel re-evalutates, the World Health Organization is expected to recommend that amalgam use be “phased down.” “We welcome WHO’s support for “phase down” , and urge FDA to do the same,” said MPP’s director. The WHO is expected to soon final its meeting report in preparation for the upcoming International Negotiations Committee deliberations in Chiba, Japan, 24-28 January, 2011, that will ultimately lead to the adoption of a legally binding instrument on mercury by 2013.